Chronic kidney disease affects hundreds of millions of people worldwide and dramatically raises the risk of heart attack, stroke, and complete kidney failure. For decades, researchers have searched for therapies that could protect both organs at once, since damage to one tends to accelerate damage to the other. A class of peptides that mimic a gut hormone called glucagon-like peptide-1 (GLP-1) has attracted intense scientific interest on exactly this front.
A 2026 systematic review and meta-analysis published in Diabetes, Obesity and Metabolism pooled data from thirteen large randomised controlled trials covering nearly 97,500 participants, roughly 32,000 of whom had confirmed chronic kidney disease. The researchers asked a focused question: across this specific population, do GLP-1 receptor agonist peptides reduce the combined burden of cardiovascular and kidney events, and does the benefit persist even when patients are already using another protective drug class?
The short answer from the pooled data is yes on both counts, with what the authors rated as high-certainty evidence. The findings are worth unpacking in detail, because the size and scope of this analysis make it one of the most comprehensive looks at cardiorenal peptide research to date.
Background on GLP-1 receptor agonists
GLP-1 is a short peptide hormone released naturally by cells in the small intestine after a meal. It signals the pancreas to release insulin, slows gastric emptying, and acts on receptors in the heart, blood vessels, and kidneys. Synthetic peptides designed to activate the same receptor, called GLP-1 receptor agonists, were first developed to manage blood sugar, but researchers began noticing effects well beyond glucose control.
Early cardiovascular outcome trials, run primarily in people with type 2 diabetes, suggested these peptides might reduce serious heart events. More recently, the landmark FLOW trial focused specifically on people with chronic kidney disease and found protective kidney signals. What had not been done before this meta-analysis was to pull all relevant randomised trial data together into a single analysis restricted to chronic kidney disease patients and then rank individual peptides against one another using a statistical technique called network meta-analysis.
How the researchers built the analysis
The team searched four major medical databases through March 2025, screening for randomised controlled trials that enrolled adults with chronic kidney disease, defined as an estimated glomerular filtration rate below 60 mL per minute per 1.73 square metres or a urinary albumin-to-creatinine ratio of 30 mg per gram or higher. Trials had to run for at least 26 weeks and compare a GLP-1 receptor agonist against a placebo.
Thirteen trials met the inclusion criteria. The primary outcomes the researchers tracked were a three-point major adverse cardiovascular event score, which combines cardiovascular death, heart attack, and stroke, and a kidney composite endpoint built around the KDIGO framework, a widely accepted international standard. They also examined kidney failure alone and a biomarker of kidney stress called the urinary albumin-to-creatinine ratio.
To account for differences across studies, the team used random-effects statistical models, which are considered more conservative than fixed-effects models. They then graded the certainty of the evidence using the GRADE system, which assesses factors like study quality, consistency across trials, and precision of estimates.
Key numbers from the pooled data
For cardiovascular events, the meta-analysis found that GLP-1 receptor agonist peptides were associated with a 16 percent reduction in three-point major adverse cardiovascular events compared with placebo. The hazard ratio was 0.84 with a 95 percent confidence interval of 0.79 to 0.89. The GRADE rating for this finding was high certainty, meaning the researchers were confident the true effect is close to this estimate.
For kidney outcomes, the picture was even more pronounced. The composite kidney endpoint showed a 21 percent relative reduction, with a hazard ratio of 0.79 and a 95 percent confidence interval of 0.73 to 0.86, again rated high certainty. When the researchers looked at kidney failure specifically, the risk reduction climbed to 28 percent, with a hazard ratio of 0.72. The urinary albumin-to-creatinine ratio, a marker of how much protein is leaking into urine and a proxy for kidney stress, fell by 26 percent on average.
On the safety side, no excess risk of acute kidney injury was observed in the GLP-1 receptor agonist groups relative to placebo. This is a notable finding because some researchers had hypothesised that rapid fluid and weight changes associated with these peptides might temporarily stress the kidneys.
The SGLT2 inhibitor question
One of the novel elements of this meta-analysis was its examination of whether a background drug class called SGLT2 inhibitors changed the results. SGLT2 inhibitors are another group of agents with demonstrated kidney and heart protection, and many patients in recent trials were already taking them.
The researchers tested for what statisticians call an interaction effect. If the GLP-1 receptor agonist benefit disappeared or shrank when patients were already on SGLT2 inhibitors, it would suggest the two classes were redundant. The interaction p-value came back at 0.41, which is far from statistically significant, indicating the cardiorenal benefits of GLP-1 receptor agonist peptides appeared consistent regardless of whether SGLT2 inhibitors were also on board. The authors described the effects as additive, meaning the literature suggests there may be complementary rather than overlapping mechanisms.
Network meta-analysis and agent rankings
Beyond the pooled pairwise comparison, the team conducted what is called a frequentist network meta-analysis. This technique allows indirect comparisons across different peptides within the same class, even when they were never directly tested against each other in the same trial. Each agent receives a surface under the cumulative ranking curve score, abbreviated SUCRA, where higher scores suggest better ranking for the outcome of interest.
In this exploratory analysis, the subcutaneous form of the peptide semaglutide achieved the highest SUCRA score for the kidney composite endpoint at 78.4 percent. Importantly, the direct evidence base for semaglutide in this outcome was rated high certainty by GRADE, lending more weight to its ranking than purely indirect comparisons would carry. The authors were careful to label the network meta-analysis findings as exploratory, since indirect comparisons carry more assumptions than head-to-head trial data.
The distinction between agents within the GLP-1 receptor agonist class matters to researchers because peptides in the same class can differ substantially in molecular half-life, dosing route, receptor binding characteristics, and tissue distribution. The ranking data, while preliminary, gives researchers a hypothesis to test in future head-to-head trials.
What the findings mean for ongoing research
This meta-analysis is notable for several reasons beyond its size. It is the first simultaneous synthesis of both cardiovascular and kidney outcomes in a population restricted to confirmed chronic kidney disease patients. Earlier reviews had combined CKD and non-CKD populations, which could dilute or obscure signals relevant to the kidney-disease subgroup specifically.
The high-certainty GRADE ratings for both primary outcomes are relatively rare in peptide research, which often relies on smaller or shorter studies. The fact that thirteen trials met the strict inclusion criteria, covering nearly 32,000 confirmed CKD participants, gives the estimates a statistical robustness that individual trials cannot achieve.
The literature suggests several possible mechanisms driving these observations. GLP-1 receptors are expressed in the glomeruli of the kidney, in endothelial cells lining blood vessels, and in cardiac tissue. Researchers hypothesise that reduced inflammation, lower oxidative stress, and haemodynamic changes in the kidney's filtration units may all contribute to the observed protection. Exactly how much each mechanism contributes remains an active area of investigation.
For the research community, the practical implication from this analysis is that chronic kidney disease may be a population where GLP-1 receptor agonist peptides deserve continued priority in large-scale trials, both as monotherapy and in combination with other protective drug classes. The additive finding alongside SGLT2 inhibitors points toward future combination studies as a logical next step.
